GLG News by Dermatolopathologists (US)
Articles with lock require a subscription to GLG News |
Request a free trial
February 27, 2007Switching Retinoids during acne therapy does improve outcomes
Analysis of: No Need to Switch Retinoids During Acne Vulgaris Treatment | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This poster at the 2007 American Academy of Dermatology meeting in Washington, DC indicates that Galderma's product, Adapalene, is as effective as Allergan's product Tazarotene. This is opposite to 2 other studies that have been done in the past indicating that Tazarotene is the most effective retinoid,...
February 26, 2007Obagi Medical Products Clenziderm should have a positive impact
Analysis of: Obagi Medical Products, Inc. Launches CLENZIderm M.D. Penetrating Acne Therapeutic System | www.pharmalive.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Obagi Medical Products Clenziderm should have a positive impact:1. It allows the physician or the medical aesthetician under the physician’s guidance to dispense an effective product without a prescription.2. Its efficacy may approach that of prescription products, and studies are needed to confirm...
February 26, 2007Ceragenix Epiceram product has good potential to be effective in eczema and other skin conditions
Analysis of: Ceragenix Completes Patient Visits for EpiCeram Clinical Study | www.pharmalive.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Ceragenix's new product Epiceram, the Barrier repair cream has potential merit and efficacy comparable to mid strength topical steroids:1. Barrier repair has been found to be antiinflammatory.2. The product in mouse studies has effects comparable to steroid creams.3. The product will have less/ minimal...
February 26, 2007CNTO 1275 will have an impact on the psoriasis market
Analysis of: Centocor, Inc. Releases Phase 2 Data on Novel Biologic CNTO 1275 Targeting Chronic Plaque Psoriasis | pharmalive.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Centocor's product CNTO1275 will have a major and sustained impact on the market:1. Its PASI 75 reduction is better than the current injectables other than Centocor's Infliximab, which requires a complicated IV infusion.2. Side effects are comparable to other agents.3. It is specifically being developed...
February 26, 2007Will the OTC laser hair systems have an impact??
Analysis of: Palomar and Gillette Expand Their Collaboration to Develop and Commercialize an Additional Light-Based Hair Removal Device for Home Use | phx.corporate-ir.net
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Implications:
Palomar and Gillette’s venture in the direct to consumer sale of a light based laser device has several issues that will effect the ability of this venture to be successful
1. The device is only approved for non facial areas, and is only temporarily effective with less than 10% reduction-...
Previous Page : 1 2 3 4 5 651 to 55 of 55
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Personal medicine is goal of Eli Lilly & Co.
www.azcentral.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008